The pharmaceutical market in 2024 saw major shifts driven by obesity, diabetes, and oncology treatments. Leading products like Merck’s Keytruda and Novo Nordisk’s Ozempic continued to dominate, while new entrants such as Eli Lilly’s Mounjaro and Zepbound reshaped the market with unprecedented growth. Here's a deep dive into the top 25 best-selling prescription drugs of the year by total sales and growth rate.
Top 25 Prescription Drugs by Global Sales in 2024
RankDrugCompany2024 Sales (USD)1KeytrudaMerck$29.5B2OzempicNovo Nordisk$17.5B3MounjaroEli Lilly$11.5B4EliquisBMS/Pfizer$11.4B5BiktarvyGilead Sciences$10.8B6DupixentSanofi/Regeneron$10.7B7DarzalexJohnson & Johnson$10.4B8StelaraJohnson & Johnson$9.7B9OpdivoBristol Myers Squibb$9.3B10TrulicityEli Lilly$8.7B11ImbruvicaAbbVie/J&J$8.3B12EntrestoNovartis$7.7B13IbrancePfizer$7.1B14RevlimidBristol Myers Squibb$6.9B15XareltoBayer/J&J$6.8B16OcrevusRoche$6.6B17TecentriqRoche$6.4B18VekluryGilead Sciences$6.2B19SkyriziAbbVie$6.0B20CosentyxNovartis$5.8B21JanuviaMerck$5.6B22SymbicortAstraZeneca$5.4B23FarxigaAstraZeneca$5.2B24ZepboundEli Lilly$5.0B25TremfyaJohnson & Johnson$4.8B
Top 25 Prescription Drugs by Growth Rate in 2024
RankDrugCompanyGrowth RateNotes1MounjaroEli Lilly+969%Massive expansion2SkyriziAbbVie+50.3%Strong immunology push3OzempicNovo Nordisk+38%Diabetes/obesity boom4DupixentSanofi/Regeneron+33.6%Consistent uptake5EntrestoNovartis+30%Heart failure growth6DarzalexJ&J+22.1%Oncology expansion7KeytrudaMerck+18%Leading cancer therapy8OcrevusRoche+16%Multiple sclerosis market9BiktarvyGilead+14%HIV dominance10StelaraJ&J+11.7%Immunology retention11OpdivoBristol Myers+9.2%Oncology growth12TremfyaJ&J+8% (est.)Psoriasis/arthritis13FarxigaAstraZeneca+6.1%Broad CV/metabolic use14TrulicityEli Lilly+4.1%GLP-1 growth15EliquisBMS/Pfizer+3.5%Stable anticoagulant16CosentyxNovartis+2% (est.)Immunology17TecentriqRoche~0% (est.)Plateauing growth18IbrancePfizer−1% (est.)Mature breast cancer19SymbicortAstraZeneca−2% (est.)Generic erosion20XareltoBayer/J&J−5.8%Competitive pressure21VekluryGilead−15% (est.)COVID-19 decline22JanuviaMerck−10% (est.)Patent loss23ImbruvicaAbbVie/J&J−17.9%Market erosion24RevlimidBMS−38.6%Major LOE hit25ZepboundEli LillyN/ALaunched late 2023
Free Membership Required
You must be a Free member to access this content.
